Upstream process intensification using perfusion cell culture has become a necessity for meeting today’s demand in monoclonal antibodies (mAbs) bioprocessing. By sustaining higher viable cell ...
Therapeutic antibodies will always be too expensive for low- and middle-income countries, unless manufacturers embrace more cost-efficient production tech. So says Peter Gardner, scientific director ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results